{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:15:39Z","timestamp":1792192539160,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":139,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtha.2023.02.029","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:08:41Z","timestamp":1678860521000},"page":"1397-1408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity"],"prefix":"10.1016","volume":"21","author":[{"given":"Anna","family":"Falanga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.02.029_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02981929","article-title":"Pathogenesis of thrombosis in patients with malignancy","volume":"73","author":"Falanga","year":"2001","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2023.02.029_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1046\/j.1538-7836.2003.00275.x","article-title":"From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer","volume":"1","author":"Levine","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","article-title":"Cancer and venous thromboembolism","volume":"6","author":"Prandoni","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2023.02.029_bib5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2023.02.029_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"Cohen","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjmed.2005.06.058","article-title":"Incidence of venous thromboembolism in patients hospitalized with cancer","volume":"119","author":"Stein","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2023.02.029_bib10","doi-asserted-by":"crossref","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Jara-Palomares L, Sinn M, Syrigos K, Young A, Jordan K, Committee EG. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline(dagger). Ann Oncol. Published online January 10, 2023. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014","DOI":"10.1016\/j.annonc.2022.12.014"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.02.029_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/07357900802656681","article-title":"Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors","volume":"27","author":"Wun","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.jtha.2023.02.029_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2011.10.025","article-title":"Anticancer treatment and thrombosis","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.02.029_bib13","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.029_bib14","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtha.2023.02.029_bib15","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.029_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/PPA.S79373","article-title":"Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study","volume":"9","author":"Noble","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2023.02.029_bib17","article-title":"How well do European patients understand cancer-associated thrombosis? A patient survey","volume":"31","author":"Falanga","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jtha.2023.02.029_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0041-1729920","article-title":"Cancer-associated atherothrombosis: the challenge","volume":"30","author":"Naschitz","year":"2021","journal-title":"Int J Angiol"},{"key":"10.1016\/j.jtha.2023.02.029_bib19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2023.02.029_bib20","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.02.029_bib21","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2023.02.029_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/a-1334-3259","article-title":"Prevention and management of thrombosis in BCR\/ABL-negative myeloproliferative neoplasms","volume":"41","author":"Falanga","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2023.02.029_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jtha.2023.02.029_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-0-387-79962-9_3","article-title":"Activation of clotting factors in cancer","volume":"148","author":"Rickles","year":"2009","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.jtha.2023.02.029_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jtha.2022.09.001","article-title":"MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism","volume":"21","author":"Anijs","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib26","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.029_bib27","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A\u00a0predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2023.02.029_bib28","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A\u00a0clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.02.029_bib29","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.thromres.2018.01.017","article-title":"Hemostatic biomarkers in cancer progression","volume":"164","author":"Falanga","year":"2018","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.02.029_bib30","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0049-3848(20)30395-9","article-title":"Hemostatic biomarkers in occult cancer and cancer risk prediction","volume":"191","author":"Marchetti","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.02.029_bib31","article-title":"Tumor-educated platelets: a review of current and potential applications in solid tumors","volume":"13","author":"Varkey","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jtha.2023.02.029_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2023.02.029_bib33","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0049-3848(16)30353-X","article-title":"The polyphosphate\/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies","volume":"141","author":"Nickel","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.02.029_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.714357","article-title":"The role of neutrophil extracellular traps in cancer","volume":"11","author":"Shao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtha.2023.02.029_bib35","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/jth.13002","article-title":"Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice","volume":"13","author":"Thomas","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib36","article-title":"Lectures on surgical pathology and therapeutics: a handbook for students and practitioners","volume":"2","author":"Billroth","year":"1878","journal-title":"New Sydenham Soc"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.02.029_bib37","article-title":"Tissue factor and cancer","volume":"130","author":"Ruf","year":"2012","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.02.029_bib38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0049-3848(12)70143-3","article-title":"Hemostatic factors, innate immunity and malignancy","volume":"129","author":"Degen","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.02.029_bib39","first-page":"3267","article-title":"Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in\u00a0vitro and tumor metastasis in\u00a0vivo","volume":"52","author":"Nierodzik","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtha.2023.02.029_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00286945","article-title":"Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases","volume":"86","author":"Gasic","year":"1976","journal-title":"Z\u00a0Krebsforsch Klin Onkol Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtha.2023.02.029_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.mehy.2005.09.004","article-title":"Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis?","volume":"66","author":"Rak","year":"2006","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jtha.2023.02.029_bib42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03357","article-title":"The MET oncogene drives a genetic programme linking cancer to haemostasis","volume":"434","author":"Boccaccio","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2023.02.029_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101349","article-title":"Blood coagulation and cancer genes","volume":"35","author":"Tawil","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtha.2023.02.029_bib44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/ATVBAHA.122.318463","article-title":"Histopathological features of cancer-associated venous thromboembolism: presence of intrathrombus cancer cells and prothrombotic factors","volume":"43","author":"Gi","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.02.029_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA Guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtha.2023.02.029_bib46","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.2022015796","article-title":"Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer","volume":"140","author":"Becattini","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.02.029_bib47","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2020003115","article-title":"Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis","volume":"4","author":"Bosch","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.02.029_bib48","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.02.029_bib49","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.02.029_bib50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2023.02.029_bib51","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/jth.15519","article-title":"Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.02.029_bib52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-pharmtox-052020-023107","article-title":"An aspirin a day: new pharmacological developments and cancer chemoprevention","volume":"63","author":"Menter","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623002313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:25Z","timestamp":1761536245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623002313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1538783623002313"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.02.029","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}